I am curious about the structure of APN01. It is human recombinant soluble ACE2 (hrsACE2) that is administered systemically in COVID-19 therapy. How is it stabilized in-vivo?
The only information I was able to find is that hrsACE2 is a highly glycosylated form. This information is available in a data bank that is not open access and I am sorry I do not have the authorization to disclose more.
There are very scarce data in the literature and aside the Lancet Respiratory Medicine Oct 2020 and Cell May 2020 papers I did not find other information.